Anti Inflammatory News and Research

RSS

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

Vitamin D may modify damaging effects of smoking on lung function

Vitamin D deficiency is associated with worse lung function and more rapid decline in lung function over time in smokers, suggesting that vitamin D may have a protective effect against the effects of smoking on lung function, according to a new study from researchers in Boston.

20 Jul 2012

Nuvo Research receives first three Pliaglis marketing licenses from E.U. countries

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that Galderma S.A. (Galderma), a global company dedicated to dermatology has received its first three Pliaglis marketing licenses from E.U. countries.

20 Jul 2012

Abscisic acid has anti-inflammatory effects in the lungs and gut

Building on previous work with the botanical abscisic acida, researchers in the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs as well as in the gut.

19 Jul 2012

Combination of tPA and 3K3A-APC may effectively treat stroke

A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy.

18 Jul 2012

Scientists clone tannin gene in sorghum

They might be called a blessing or a curse -- tannins, which are present in certain sorghums, contain health-promoting antioxidant properties, but also provide a bitter taste and decreased protein digestibility. To better understand tannins, their role in sorghum and how they can be altered to improve sorghum's use as food and feed, a team of scientists led by Kansas State University and U.S. Department of Agriculture researchers, has cloned the tannin gene in sorghum.

14 Jul 2012

Vitamin D deficiency may impair lung function in asthmatic children treated with budesonide

Vitamin D deficiency is associated with poorer lung function in asthmatic children treated with inhaled corticosteroids, according to a new study from researchers in Boston.

14 Jul 2012

Researchers define interaction between two essential proteins that control inflammation

Researchers at the IRCM, led by geneticist Dr. Jacques Drouin, recently defined the interaction between two essential proteins that control inflammation.

14 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

12 Jul 2012

SLU professor to study how antithrombin might prevent premature death from heart disease

Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

12 Jul 2012

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent International AB today announced data from the GLACIER phase IIa study evaluating BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is developing BI-204 in collaboration with Genentech, a member of the Roche Group.

11 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

10 Jul 2012

Cannabis use may reduce mortality risk in psychosis patients

Cannabis use is associated with reduced mortality risk in patients with psychotic disorders, study results suggest.

10 Jul 2012

Study clarifies anti-inflammatory impact of boswellic acids

It was one of the gifts of the Magi - in addition to myrrh and gold they offered frankincense to the newly born baby Jesus. Since the ancient world the aromatic fragrance of burning Boswellia resin has been part of many religious ceremonies and is still used as a means to indicate special festive atmosphere in the church today. But frankincense can do much more: "The resin from the trunk of Boswellia trees contains anti-inflammatory substances," Professor Dr. Oliver Werz of the Friedrich Schiller University Jena (Germany) says.

10 Jul 2012

EGF helps prevent inflammation-induced cancer

Epidermal growth factor (EGF) is a protein that normally regulates intestinal healing. However, biological therapies, like EGF, also may pose the risk of increasing the possibility of cancer. Philip Dubé, PhD, and Brent Polk, MD, both of the Saban Research Institute of Children's Hospital Los Angeles have demonstrated that in preclinical models, EGF encourages healing and provides powerful anti-inflammatory properties that prevent inflammation-induced cancer.

10 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012